Evaluation of Blood Coagulation Parameters in Chronic Kidney Diseases

Main Article Content

Ahmad Q. Jaradat
Futoon A. Al-Rawashde
Marah Alsarayreh
Rama Q. Jaradat
Heba Y. Al-Radaideh
Khaled M. Khleifat

Abstract

Patients with chronic kidney disease (CKD) are prone to haemorrhage and/or thrombi formation, suggesting abnormalities in haemostasis. The study aimed to investigate the impairment of coagulation factors in CKD patients. One hundred and twenty-three (123) CKD patients, who were attending Prince Hamza and Al-Karak public hospitals, and fifty (50) healthy subjects (control) were recruited for the study. CKD patients were subcategorized according to their GFR value into III B and IV groups. Ethical approval was obtained, and all participants consented to the study. Whole blood samples were collected from all the CKD patients and 50 control (healthy) subjects and tested for prothrombin time (PT), activated partial thromboplastin time (aPTT), and coagulation factors I (fibrinogen), II, V, VII, VIII, IX, X, XI, and anti-thrombin III (ATIII) on STA coagulation analyzer. The levels of proteins C, S, and von Willebrand factor (VWF) were measured using enzyme-linked immunosorbent assay (ELISA). The findings showed a significant prolonged PT and aPTT in CKD patients compared to the control (healthy) subjects, and the level of F-V and F-XI were significantly decreased, justifying the clinical manifestation of bleeding in CKD patients. However, factors VII, VIII, and IX were increased significantly in CKD patients. The findings from this study have demonstrated that CKD impairs the coagulation factors and leads to an increase in the time required for clot formation, suggesting a tendency of patients with CKD to have frequent bleeding episodes. 

Downloads

Download data is not yet available.

Article Details

How to Cite
Jaradat, A. Q., Al-Rawashde, F. A., Alsarayreh, M., Jaradat, R. Q., Al-Radaideh, H. Y., & Khleifat, K. M. (2024). Evaluation of Blood Coagulation Parameters in Chronic Kidney Diseases . Tropical Journal of Natural Product Research (TJNPR), 8(12), 9430 – 9436. https://doi.org/10.26538/tjnpr/v8i12.11
Section
Articles

How to Cite

Jaradat, A. Q., Al-Rawashde, F. A., Alsarayreh, M., Jaradat, R. Q., Al-Radaideh, H. Y., & Khleifat, K. M. (2024). Evaluation of Blood Coagulation Parameters in Chronic Kidney Diseases . Tropical Journal of Natural Product Research (TJNPR), 8(12), 9430 – 9436. https://doi.org/10.26538/tjnpr/v8i12.11

References

Jalal DI, Chonchol M, Targher G. Disorders of hemostasis associated with chronic kidney disease. Semin Thromb Hemost. 2010; 36(1):34-40.

Rinder HM. Hemostasis and coagulation. Clin Lab Med. 2009; 29(2):xi.

Sang Y, Roest M, de Laat B, de Groot PG, Huskens D. Interplay between platelets and coagulation. Blood Rev. 2021; 46:100733.

Sierra C, Moreno M, García-Ruiz JC. The physiology of hemostasis. Blood Coagul Fibrinolysis. 2022; 33(Suppl 1):S1-S2.

Palta S, Saroa R, Palta A. Overview of the coagulation system. Indian J Anaesth. 2014; 58(5):515-523.

Lenting PJ, Christophe OD, Denis CV. von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends. Blood. 2015; 125(13):2019-2028.

Butenas S and Mann KG. Blood coagulation. Biochemistry Biokhim. 2002; 67(1):3-12.

Smith SA, Travers RJ, Morrissey JH. How it all starts: Initiation of the clotting cascade. Crit Rev Biochem Mol Biol. 2015; 50(4):326-336.

Vojacek JF. Should We Replace the Terms Intrinsic and Extrinsic Coagulation Pathways With Tissue Factor Pathway? Clin Appl Thromb Hemost. 2017;23(8):922-927.

Neuenschwander PF and Morrissey JH. Roles of the membrane-interactive regions of factor VIIa and tissue factor. The factor VIIa Gla domain is dispensable for binding to tissue factor but important for activation of factor X. The J Biol Chem. 1994; 269(11):8007-8013.

Tavoosi N, Smith SA, Davis-Harrison RL, Morrissey JH. Factor VII and protein C are phosphatidic acid-binding proteins. Biochem. 2013; 52(33):5545-5552.

Mohanty D, Ghosh K, Nandwani SK, Shetty S, Phillips C, Rizvi S, et al. Fibrinolysis, inhibitors of blood coagulation, and monocyte derived coagulant activity in acute malaria. Am J Hematol. 1997; 54(1):23-29.

Kordich LC, Forastiero RR, Basilotta E, Porterie P, Carreras LO. Natural inhibitors of blood coagulation and fibrinolysis in patients with lupus anticoagulant. Blood Coagul Fibrinolysis. 1992; 3(6):765-771.

Oto J, Fernández-Pardo Á, Miralles M, Plana E, España F, Navarro S, et al. Activated protein C assays: A review. Clin Chim Acta. 2020; 502:227-232.

Gierula M and Ahnström J. Anticoagulant protein S-New insights on interactions and functions. J Thromb Haemost. 2020; 18(11):2801-2811.

Hepner M and Karlaftis V. Antithrombin. Meth Mol Biol. 2013; 992:355-364.

Roderick P, Davies R, Jones C, Feest T, Smith S, Farrington K. Simulation model of renal replacement therapy: predicting future demand in England. Nephrol Dial Transplant. 2004; 19(3):692-701.

Pavord S and Myers B. Bleeding and thrombotic complications of kidney disease. Blood Rev. 2011; 25(6):271-278.

Garba MS, Bouderbala S, Kharoubi O. Olive Cake Prevents Inflammation, Modulates Glomerulopathy, Glomerular Filtration Rate and Improves Renal Functions in Adult Obese Rats Fed a High-Fat Diet Since Weaning. Trop J Nat Prod Res. 2024; 8(8):7956 -7964.

Alhawamdeh M, Alsarayreh A, Qaisi YA, Masood A, Ahawamdeh N, Alhroob H. In Vivo Comparative Study Between Articaine and Mepivacaine on Hepatic and Pancreatic Function Using Diabetic Rat Model. Trop J Nat Prod Res. 2024; 8(7):7672 -7676.

Kien DX, Ha DV, Kien PT, Huy THA, Nga NT, Dung VM, Toan TD, Anh NP, Ngan NH. Blood Glucose Lowering Effect of Lagerstroemia speciosa L. Leaves Extract on Type 2 Diabetic Rat Model. Trop J Nat Prod Res. 2024; 8(7):7709-7714.

K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002; 39(2 Suppl 1):S1-266.

Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, De Zeeuw D, Hostetter TH, Lameire N, Eknoyan G. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005; 67(6):2089-2100.

Ammirati AL. Chronic Kidney Disease. Revista da Associacao Medica Brasileira (1992). 2020; 66Suppl 1(Suppl 1):s03-s9.

Ali AS, Nageye YA, Bello KE. Investigating the Effects of Aqueous Leaf Extracts from Moringa oleifera and Carica papaya on Chloramphenicol-Induced Anaemia in Wistar Rats. Trop J Nat Prod Res. 2024; 8(7):7765 -7769.

Soliman NA, Mansour SW, Ammar MA, Hassan NA, Mohamed RHA. Ameliorative Effect of Pomegranate Molasses on Phenylhydrazine-Induced Anemia in Rats. Trop J Nat Prod Res. 2024; 8(7):7909 - 7914.

Boccardo P, Remuzzi G, Galbusera M. Platelet dysfunction in renal failure. Semin Thromb Hemost. 2004; 30(5):579-589.

Lutz J, Menke J, Sollinger D, Schinzel H, Thürmel K. Haemostasis in chronic kidney disease. Nephrol Dial Transplant. 2014; 29(1):29-40.

Moal V, Brunet P, Dou L, Morange S, Sampol J, Berland Y. Impaired expression of glycoproteins on resting and stimulated platelets in uraemic patients. Nephrol Dial Transplant. 2003; 18(9):1834-1841.

Lisman T and Intagliata NM. Bleeding and Thrombosis in Patients with Liver Diseases. Semin Thromb Hemost. 2020; 46(6):653-655.

Peyvandi F, Garagiola I, Young G. The past and future of haemophilia: diagnosis, treatments, and its complications. Lancet. 2016; 388(10040):187-197.

Campello E, Spiezia L, Simioni P. Diagnosis and management of factor V Leiden. Expert Rev Hematol. 2016; 9(12):1139-1149.

Iba T and Levy JH. Inflammation and thrombosis: roles of neutrophils, platelets and endothelial cells and their interactions in thrombus formation during sepsis. J Thromb Haemost. 2018; 16(2):231-241.

Adelborg K, Larsen JB, Hvas AM. Disseminated intravascular coagulation: epidemiology, biomarkers, and management. Br J Haematol. 2021; 192(5):803-818.

Mikhail A, Brown C, Williams JA, Mathrani V, Shrivastava R, Evans J, Isaac H, Bhandari S. Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease. BMC Nephrol. 2017; 18(1):345.

Pavlou EG, Georgatzakou HT, Fortis SP, Tsante KA, Tsantes AG, Nomikou EG, Kapota AI, Petras DI, Venetikou MS, Papageorgiou EG, Antonelou MH, Kriebardis AG. Coagulation Abnormalities in Renal Pathology of Chronic Kidney Disease: The Interplay between Blood Cells and Soluble Factors. Biomolecules. 2021; 11(9):1309.

Gäckler A, Rohn H, Lisman T, Benkö T, Witzke O, Kribben A, Saner FH. Evaluation of hemostasis in patients with end-stage renal disease. PloS One. 2019; 14(2):e0212237.

Grover SP and Mackman N. Intrinsic Pathway of Coagulation and Thrombosis. Arterioscler Thromb Vasc Biol. 2019; 39(3):331-338.

Dahlbäck B. Novel insights into the regulation of coagulation by factor V isoforms, tissue factor pathway inhibitorα, and protein S. J Thromb Haemost. 2017; 15(7):1241-1250.

Shlipak MG, Fried LF, Crump C, Bleyer AJ, Manolio TA, Tracy RP, Furberg CD, Psaty BM. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation. 2003; 107(1):87-92.

Lim HY, Lui B, Tacey M, Barit D, Patel SK, Donnan G, Nandurkar H, Burrell LM, Ho P. Global coagulation assays in patients with chronic kidney disease and their role in predicting thrombotic risk. Thromb Res. 2023; 226:127-135.